Karen Lewis - 16 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief People Officer
Signature: /s/ David Watson, attorney-in-fact for Karen Lewis
Issuer symbol: APLS
Transactions as of: 16 Jan 2024
Net transactions value: +$1,526,324
Form type: 4
Filing time: 17 Jan 2024, 16:43:45 UTC
Previous filing: 02 Jun 2023
Next filing: 18 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+16,963	+41%	$0.000000	58,569	16 Jan 2024	Direct	F1
transaction	APLS	Common Stock	Sale	$109,032	-1,632	-2.8%	$66.81	56,937	16 Jan 2024	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$1,635,356	+24,666		$66.30	24,666	16 Jan 2024	Common Stock	24,666	$66.30	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
F2	This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
F3	This includes 102 shares from the 10/31/23 ESPP Purchase
F4	This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.